The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Hospital Infection Therapeutics-Global Market Insights and Sales Trends 2024
Synopsis
Hospital-acquired infections, also known as nosocomial infections, are acquired by patients in the hospitals or healthcare facilities. Urinary tract infections, bloodstream infections, surgical-site infections, Clostridium difficile associated diarrhea, and pneumonia are examples of nosocomial infections.
The global Hospital Infection Therapeutics market size is expected to reach US$ 3240.4 million by 2029, growing at a CAGR of 2.5% from 2023 to 2029. The market is mainly driven by the significant applications of Hospital Infection Therapeutics in various end use industries. The expanding demands from the Hospital Acquired Pneumonia, Surgical Site Infections, Urinary Tract Infection and Gastrointestinal Disorders, are propelling Hospital Infection Therapeutics market. Antibacterial Drugs, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Antiviral Drugs segment is estimated at % CAGR for the next seven-year period.
The global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Hospital Infection Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Hospital Infection Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Hospital Infection Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Hospital Infection Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Hospital Infection Therapeutics covered in this report include Bayer, Johnson & Johnson Services, Actavis, Sanofi, Bristol Myers Squibb Company, AstraZeneca, Pfizer, Merck and GlaxoSmithkline, etc.
The global Hospital Infection Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Bayer
Johnson & Johnson Services
Actavis
Sanofi
Bristol Myers Squibb Company
AstraZeneca
Pfizer
Merck
GlaxoSmithkline
Cubist Pharmaceuticals
Global Hospital Infection Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Hospital Infection Therapeutics market, Segment by Type:
Antibacterial Drugs
Antiviral Drugs
Antifungal Drugs
Global Hospital Infection Therapeutics market, by Application
Hospital Acquired Pneumonia
Surgical Site Infections
Urinary Tract Infection
Gastrointestinal Disorders
Bloodstream Infections
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Hospital Infection Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Hospital-acquired infections, also known as nosocomial infections, are acquired by patients in the hospitals or healthcare facilities. Urinary tract infections, bloodstream infections, surgical-site infections, Clostridium difficile associated diarrhea, and pneumonia are examples of nosocomial infections.
The global Hospital Infection Therapeutics market size is expected to reach US$ 3240.4 million by 2029, growing at a CAGR of 2.5% from 2023 to 2029. The market is mainly driven by the significant applications of Hospital Infection Therapeutics in various end use industries. The expanding demands from the Hospital Acquired Pneumonia, Surgical Site Infections, Urinary Tract Infection and Gastrointestinal Disorders, are propelling Hospital Infection Therapeutics market. Antibacterial Drugs, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Antiviral Drugs segment is estimated at % CAGR for the next seven-year period.
The global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Hospital Infection Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Hospital Infection Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Hospital Infection Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Hospital Infection Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Hospital Infection Therapeutics covered in this report include Bayer, Johnson & Johnson Services, Actavis, Sanofi, Bristol Myers Squibb Company, AstraZeneca, Pfizer, Merck and GlaxoSmithkline, etc.
The global Hospital Infection Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Bayer
Johnson & Johnson Services
Actavis
Sanofi
Bristol Myers Squibb Company
AstraZeneca
Pfizer
Merck
GlaxoSmithkline
Cubist Pharmaceuticals
Global Hospital Infection Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Hospital Infection Therapeutics market, Segment by Type:
Antibacterial Drugs
Antiviral Drugs
Antifungal Drugs
Global Hospital Infection Therapeutics market, by Application
Hospital Acquired Pneumonia
Surgical Site Infections
Urinary Tract Infection
Gastrointestinal Disorders
Bloodstream Infections
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Hospital Infection Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Hospital Infection Therapeutics
1.1 Hospital Infection Therapeutics Market Overview
1.1.1 Hospital Infection Therapeutics Product Scope
1.1.2 Hospital Infection Therapeutics Market Status and Outlook
1.2 Global Hospital Infection Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Hospital Infection Therapeutics Market Size by Region (2018-2029)
1.4 Global Hospital Infection Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global Hospital Infection Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Hospital Infection Therapeutics Market Size (2018-2029)
1.6.1 North America Hospital Infection Therapeutics Market Size (2018-2029)
1.6.2 Europe Hospital Infection Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific Hospital Infection Therapeutics Market Size (2018-2029)
1.6.4 Latin America Hospital Infection Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa Hospital Infection Therapeutics Market Size (2018-2029)
2 Hospital Infection Therapeutics Market by Type
2.1 Introduction
2.1.1 Antibacterial Drugs
2.1.2 Antiviral Drugs
2.1.3 Antifungal Drugs
2.2 Global Hospital Infection Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Hospital Infection Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global Hospital Infection Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Hospital Infection Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Hospital Infection Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Hospital Infection Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Hospital Infection Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Hospital Infection Therapeutics Revenue Breakdown by Type (2018-2029)
3 Hospital Infection Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Hospital Acquired Pneumonia
3.1.2 Surgical Site Infections
3.1.3 Urinary Tract Infection
3.1.4 Gastrointestinal Disorders
3.1.5 Bloodstream Infections
3.1.6 Others
3.2 Global Hospital Infection Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Hospital Infection Therapeutics Historic Market Size by Application (2018-2023)
3.2.2 Global Hospital Infection Therapeutics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Hospital Infection Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Hospital Infection Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Hospital Infection Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Hospital Infection Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Hospital Infection Therapeutics Revenue Breakdown by Application (2018-2029)
4 Hospital Infection Therapeutics Competition Analysis by Players
4.1 Global Hospital Infection Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Hospital Infection Therapeutics as of 2022)
4.3 Date of Key Players Enter into Hospital Infection Therapeutics Market
4.4 Global Top Players Hospital Infection Therapeutics Headquarters and Area Served
4.5 Key Players Hospital Infection Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Hospital Infection Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Bayer
5.1.1 Bayer Profile
5.1.2 Bayer Main Business
5.1.3 Bayer Hospital Infection Therapeutics Products, Services and Solutions
5.1.4 Bayer Hospital Infection Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 Bayer Recent Developments
5.2 Johnson & Johnson Services
5.2.1 Johnson & Johnson Services Profile
5.2.2 Johnson & Johnson Services Main Business
5.2.3 Johnson & Johnson Services Hospital Infection Therapeutics Products, Services and Solutions
5.2.4 Johnson & Johnson Services Hospital Infection Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 Johnson & Johnson Services Recent Developments
5.3 Actavis
5.3.1 Actavis Profile
5.3.2 Actavis Main Business
5.3.3 Actavis Hospital Infection Therapeutics Products, Services and Solutions
5.3.4 Actavis Hospital Infection Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 Sanofi Recent Developments
5.4 Sanofi
5.4.1 Sanofi Profile
5.4.2 Sanofi Main Business
5.4.3 Sanofi Hospital Infection Therapeutics Products, Services and Solutions
5.4.4 Sanofi Hospital Infection Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 Sanofi Recent Developments
5.5 Bristol Myers Squibb Company
5.5.1 Bristol Myers Squibb Company Profile
5.5.2 Bristol Myers Squibb Company Main Business
5.5.3 Bristol Myers Squibb Company Hospital Infection Therapeutics Products, Services and Solutions
5.5.4 Bristol Myers Squibb Company Hospital Infection Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 Bristol Myers Squibb Company Recent Developments
5.6 AstraZeneca
5.6.1 AstraZeneca Profile
5.6.2 AstraZeneca Main Business
5.6.3 AstraZeneca Hospital Infection Therapeutics Products, Services and Solutions
5.6.4 AstraZeneca Hospital Infection Therapeutics Revenue (US$ Million) & (2018-2023)
5.6.5 AstraZeneca Recent Developments
5.7 Pfizer
5.7.1 Pfizer Profile
5.7.2 Pfizer Main Business
5.7.3 Pfizer Hospital Infection Therapeutics Products, Services and Solutions
5.7.4 Pfizer Hospital Infection Therapeutics Revenue (US$ Million) & (2018-2023)
5.7.5 Pfizer Recent Developments
5.8 Merck
5.8.1 Merck Profile
5.8.2 Merck Main Business
5.8.3 Merck Hospital Infection Therapeutics Products, Services and Solutions
5.8.4 Merck Hospital Infection Therapeutics Revenue (US$ Million) & (2018-2023)
5.8.5 Merck Recent Developments
5.9 GlaxoSmithkline
5.9.1 GlaxoSmithkline Profile
5.9.2 GlaxoSmithkline Main Business
5.9.3 GlaxoSmithkline Hospital Infection Therapeutics Products, Services and Solutions
5.9.4 GlaxoSmithkline Hospital Infection Therapeutics Revenue (US$ Million) & (2018-2023)
5.9.5 GlaxoSmithkline Recent Developments
5.10 Cubist Pharmaceuticals
5.10.1 Cubist Pharmaceuticals Profile
5.10.2 Cubist Pharmaceuticals Main Business
5.10.3 Cubist Pharmaceuticals Hospital Infection Therapeutics Products, Services and Solutions
5.10.4 Cubist Pharmaceuticals Hospital Infection Therapeutics Revenue (US$ Million) & (2018-2023)
5.10.5 Cubist Pharmaceuticals Recent Developments
6 North America
6.1 North America Hospital Infection Therapeutics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Hospital Infection Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Hospital Infection Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Hospital Infection Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Hospital Infection Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Hospital Infection Therapeutics Market Dynamics
11.1 Hospital Infection Therapeutics Industry Trends
11.2 Hospital Infection Therapeutics Market Drivers
11.3 Hospital Infection Therapeutics Market Challenges
11.4 Hospital Infection Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
